Irvine-based device maker Axonics Modulation Technologies Inc. completed a $20.5 million second closing of its series C, bringing the total amount of capital raised for the round to $35 million.
Proceeds will be used to conduct a clinical trial in overactive bladder patients, to support a bid for FDA approval of the company’s rechargeable sacral neuromodulation system to treat urinary and bowel dysfunction.
Axonics got approval last year to market the product in Europe and Canada.
